Recent News

• 06.02.2025 - Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
• 06.02.2025 - Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
• 05.29.2025 - Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
• 05.29.2025 - Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
• 05.12.2025 - Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.12.2025 - Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.07.2025 - Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
• 05.07.2025 - Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
• 05.07.2025 - May 7, 2025 - May 8, 2025 : Citizens Life Sciences Conference
• 05.07.2025 - May 7, 2025 - May 8, 2025 : Citizens Life Sciences Conference

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.09.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.15.2025 - ARS Annual Report to Security Holders
• 04.15.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material